Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01228851
Other study ID # 30775
Secondary ID
Status Completed
Phase N/A
First received August 31, 2010
Last updated July 26, 2011
Start date August 2010
Est. completion date February 2011

Study information

Verified date July 2011
Source Rehabilitation Institute of Chicago
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the facilitation of balance in Parkinson's disease (PD) patients using the Nintendo Wii fit, with the ultimate goal of developing a program for function and fitness in this patient population. In this study, PD patients will participate in group exercise classes using the Wii Fit and the effects on balance, postural sway, and quality of life assessed.


Description:

The study is a cohort study using outpatients with Parkinson's Disease in Hoen and Yahr Stage 2.5 - 3. Participants will have pre- and post-exercise testing, as well as participate in an 8-week balance-training program.

Subjects Subjects will be recruited from the outpatient clinics (physician, therapy) at the Rehabilitation Institute of Chicago (RIC) as well as the Northwestern Movement Disorders Clinic, through the Department of Neurology. Approximately 20 subjects will be screened for inclusion from these institutions and 12 subjects will be enrolled in the study. (see Power analysis below).

Recruitment Procedures

Potential subjects will be approached by their treating outpatient physician (Physiatrist or Neurologist) or Physical or Occupational Therapist to see if they would be interested in participating in the study. The principal investigator will also send introductory letters to his outpatients at RIC informing them of the study. Letters will only be sent to the PI's patients (Dr. Marciniak, Dr. Toledo). Potential subjects will be educated regarding study procedures, risks and benefits, and privacy risks. Informed consent will be obtained only during initial screening and signed if the patient is interested in proceeding. Eligibility criteria will be screened for (See below). Subjects who lack decisional capacity will not included in the study.

Study Procedures This study will involve an initial visit (Visit 1) for screening and baseline data collection. The therapy/intervention sessions will be held 3 times per week for 8 weeks, (Visits 2 - 25), and there will be 1 post-intervention visit for data collection (Visit 26). Subjects will be reimbursed 11 dollars for parking expenses that will be mailed to them weekly in the form of a check. All visits will take place at Abbott Hall, 3rd floor exercise room and all visits will take approximately 1 ½ hrs.

Visit 1

Following consent, the following baseline measures will be performed:

1. Physician screening with a medical history (including falls in the month prior to the visit) and physical examination

2. Mini Mental Status Examination (MMSE)

3. Hoehn and Yahr Staging

4. Questionnaires:

1. Activities-Specific Balance Scale

2. Parkinson's Disease Quality of Life measure (PDQ-8 c. Geriatric Depression Scale.

5. Berg Balance Scale, performed by a trained physical therapist

6. Dynamic Gait Index, performed by the physical therapist

7. Gait and mobility subscales of the UPDRS

8. Sharpened Romberg with eyes open and closed

9. Balance will also be measured using the Wii balance board. Subjects will stand on the board and a gait belt will be placed around their waist. Subjects will have an accelerometer (done via smart phone) clipped to their waist to measure sway, they will stand on the Wii board, and the subject's ability to performing a reaching task will be assessed, as measured by postural sway.

The investigator will remain immediately next to the subject during the testing procedures for safety purposes with the gait belt in place, and a balance bar will also be next to the patient during the testing procedures.

Visits 2- 25 (3x/ week for 8 weeks) (Within 2 weeks of initial testing) The subjects will be seen at the Wirtz Sports Center exercise room. They will participate in 3 Wii balance board games: a marble game, a skiing game, and a bubble game. Each subject will stand on a balance board and participate in each of the 3 games for 10 minutes per game with 10 minutes rest in between each of the games, a total of 30 minutes of balance training time per session. Subjects will have a gait belt in place during the exercises, and will be supervised by a physical therapist or research assistant. Either the Physical therapist or Research Assistant will always be immediately next to the subjects during the training program. A balance bar will also be next to the subject if needed for balance.

Weekly, subjects will be asked about any changes in medications or falls that they may have experienced at home or in the community.

Visit 26

Subjects will seen for follow up assessments within 2 weeks of the final training session and the following tests repeated:

1. Interval history (including falls), exam, Hoehn and Yahr Staging

2. Questionnaires:

1. Activities-Specific Balance Scale

2. PDQ-8

3. Geriatric Depression Scale.

3. Berg Balance Scale

4. Dynamic Gait Index

5. United Parkinson Disease Rating Scale, subscales

6. Sharpened Romberg

7. Wii Balance Board Testing


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date February 2011
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Adult, 18 years or greater

2. The patient is able to provide informed consent.

3. Definitive Idiopathic Parkinson's Disease as diagnosed by a Neurologist

4. Hoehn and Yahr Stage 2.5-3

5. Able to ambulate at least 150 ft without an assistive device per patient report

6. On stable doses of Parkinson's medications for at least 2 weeks prior to study onset

7. Endurance sufficient to stand at least 20 minutes unassisted per patient report

Exclusion Criteria:

1. Mini Mental Status Exam (MMSE) < 24

2. Anticipated change in Parkinson's medications in the duration of study

3. Uncontrolled orthostasis

4. Symptomatic coronary artery disease

5. Fracture of lower limb within 6 months prior to study onset

6. Other neurologic diagnosis, including Multiple Sclerosis

7. Other vestibular disease

8. Untreated severe depression (depression of greater than or equal 20 on the Geriatric Depression Scale)

9. Acute illness

10. History of, or current, alcohol abuse

11. Significant visual impairment that would inhibit ability to participate in study, with distance vision >20/40

12. Drug induced or inherited Parkinson's Disease

13. Physical therapy within the month prior to study entry

14. Use of the Wii balance board at home as an exercise program

15. Significant camptocormia

16. Physical Therapy during the study duration

17. Any medical condition which the physician investigator determines would compromise the safety of exercise program for the subject.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Balance Training
Group balance training sessions three times a week for 8 weeks

Locations

Country Name City State
United States Rehabilitation Institute of Chicago Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Rehabilitation Institute of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Berg Balance Scale 8 weeks Yes
Secondary Dynamic Gait Index 8 weeks Yes
Secondary Parkinson's Disease QOL Questionnaire (PDQ-8) 8 weeks No
Secondary Postural Sway 8 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Completed NCT02874274 - Vaccination Uptake (VAX) in PD N/A
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A